Repligen (NASDAQ:RGEN) Price Target Cut to $135.00 by Analysts at Jefferies Financial Group

Key Points

• Jefferies Financial Group has lowered the target price for Repligen from $145.00 to $135.00, maintaining a "hold" rating on the stock, which suggests a potential upside of 12.96% from its current price.
• Repligen stock has seen mixed ratings from several analysts, with a consensus target price of $166.67 and a current rating of "Moderate Buy."
• The biotechnology company reported earnings of $0.37 per share for the last quarter, slightly below the consensus estimate, but it achieved year-over-year revenue growth of 14.8%.

Repligen (NASDAQ:RGEN - Free Report) had its price objective decreased by Jefferies Financial Group from $145.00 to $135.00 in a research note issued to investors on Friday morning,Benzinga reports. Jefferies Financial Group currently has a hold rating on the biotechnology company's stock.

RGEN has been the subject of several other reports. Evercore ISI reduced their price target on Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target for the company. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Wells Fargo & Company dropped their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Finally, HC Wainwright reissued a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, Repligen has an average rating of "Moderate Buy" and a consensus price target of $166.67.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $3.10 during mid-day trading on Friday, hitting $122.85. The company had a trading volume of 433,830 shares, compared to its average volume of 774,985. The company has a market capitalization of $6.91 billion, a price-to-earnings ratio of -488.16, a P/E/G ratio of 2.10 and a beta of 1.07. Repligen has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The stock's 50-day moving average price is $120.34 and its 200-day moving average price is $127.21.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insider Transactions at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the company's stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC lifted its stake in Repligen by 49.7% during the second quarter. Squarepoint Ops LLC now owns 73,792 shares of the biotechnology company's stock worth $9,178,000 after purchasing an additional 24,510 shares during the last quarter. Headlands Technologies LLC bought a new stake in Repligen during the second quarter worth about $353,000. Tower Research Capital LLC TRC lifted its stake in Repligen by 14.1% during the second quarter. Tower Research Capital LLC TRC now owns 1,448 shares of the biotechnology company's stock worth $180,000 after purchasing an additional 179 shares during the last quarter. Captrust Financial Advisors lifted its stake in Repligen by 16.8% during the second quarter. Captrust Financial Advisors now owns 6,566 shares of the biotechnology company's stock worth $817,000 after purchasing an additional 946 shares during the last quarter. Finally, Tidal Investments LLC increased its holdings in shares of Repligen by 13.7% in the second quarter. Tidal Investments LLC now owns 5,160 shares of the biotechnology company's stock worth $642,000 after buying an additional 621 shares during the period. Institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.